Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy
Decreased Bone Density (right panel)
September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA) has just strengthened the warning for the type 2 diabetes medicines containing canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone …